Research Article: Inhibition of ATM with KU- Sensitizes Endometrial Cancer Cell Lines to Olaparib

Abstract:
Endometrial cancer (EC) is a type of epithelial malignant tumors occurring in the endometrium. It is one of the most prevalent gynecologic cancers, which poses a serious threat to women’s health and lines the fourth after mammary glands cancer, lung cancer and rectum cancer., EC can be classified basically into two types based on Bokhman’s classification complemented with detailed genetic, biochemical and histopathological studies. Type I EC represents high expression of estrogen and progesterone receptors, low histological differentiation and presenting as an early-stage disease. Type II EC represents a highly aggressive and invasive cancer with lower expression of estrogen and progesterone receptors than type I, commonly presenting as an advanced-stage disease.– Compared to other malignancies, endometrial cancer often presents with early clinical symptoms, leading to early diagnosis in most cases. After systemic therapy, most endometrial cancer patients have a good prognosis and a low recurrence rate. However, if the cancer does recur, the prognosis is often poor. Surgical excision is an effective therapeutic means for early EC. But for recurrent EC, chemotherapy is the preferred option. Paclitaxel combined with carboplatin is more effective and better tolerated than triple therapy with doxorubicin and cisplatin for patients at the time of first recurrence. In addition to the above-mentioned chemotherapeutic agents, topotecan and docetaxel have also shown activity in recurrent endometrial cancer, although response rates have been disappointingly low.

No summary available.